公开(公告)号：WO2023288241A1

公开(公告)日：2023-01-19

申请号：PCT/US2022/073671

申请日：2022-07-13

Applicant: GENENTECH, INC.

Inventor： GAMPA, Gautham ,  HOSSEINI, Iraj ,  HUSENI, Mahrukh ,  KOERBER, James, Thomas ,  PAYANDEH, Jian, Mehr-dean ,  RUTZ, Sascha ,  SUN, Yonglian ,  CHIU, Cecilia, Pui Chi ,  DELFINO, Teresita, Arenzana

IPC: C07K16/28 ,  A61P35/00 ,  A61K2039/507 ,  C07K16/2827 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides anti-CCR8 antibodies, and compositions and methods of their preparation and use.

公开(公告)号：WO2023278377A1

公开(公告)日：2023-01-05

申请号：PCT/US2022/035220

申请日：2022-06-28

Applicant: SEAGEN INC.

Inventor： DIOLAITI, Daniel ,  GARDAI, Shyra

IPC: A61K39/395 ,  A61P35/02 ,  C07K16/28 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2866 ,  C07K16/2875 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with a nonfucosylated anti-CD70 antibody in combination with a CD47 antagonist.

公开(公告)号：WO2022243536A1

公开(公告)日：2022-11-24

申请号：PCT/EP2022/063774

申请日：2022-05-20

Applicant: LEO PHARMA A/S

Inventor： URSØ, Birgitte ,  SAJID, Waseem ,  LOVATO, Paola ,  BAGGER, Heidi Westh ,  ERKEL, Christoph ,  NUSSBAUMER, Petra ,  SCHUSTER, Simon

IPC: C07K16/28 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present disclosure provides novel antibodies against IL-1RAcP.

公开(公告)号：WO2022238963A2

公开(公告)日：2022-11-17

申请号：PCT/IB2022/054447

申请日：2022-05-12

Applicant: CRISPR THERAPEUTICS AG

Inventor： TERRETT, Jonathan Alexander ,  DEQUEANT, Mary-Lee ,  WILL, Matthias

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/828 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/892 ,  A61K35/17 ,  A61K39/001138 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2319/03 ,  C12N15/1138 ,  C12N15/625 ,  C12N2310/20 ,  C12N5/0636

Abstract: A method for treating a solid tumor (e.g., a CD70+ solid tumor) comprising one or more cycles of treatment, each cycle comprising administering to a human patient in need thereof an effective amount of a population of genetically engineered T cells after a lymphodepleting therapy, and optionally a treatment comprising an anti-CD38 antibody. The population of genetically engineered T cells comprises T cells expressing a chimeric antigen receptor (CAR) that binds CD70.

公开(公告)号：WO2022192531A2

公开(公告)日：2022-09-15

申请号：PCT/US2022/019742

申请日：2022-03-10

Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH ,  FARAG, Ahmed Karim

Inventor： BAUM, Patrick ,  VISVANATHAN, Sudha

IPC: C12Q1/6883 ,  G01N33/53 ,  C07K16/2866 ,  C07K2317/24 ,  C12Q1/6869 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2800/205 ,  G01N2800/52 ,  G01N33/564

Abstract: This invention generally relates to biomarkers associated with anti-IL-36R antibody treatment in generalized pustular psoriasis (GPP). The invention also relates to methods of using the biomarkers disclosed.

公开(公告)号：WO2022133191A2

公开(公告)日：2022-06-23

申请号：PCT/US2021/063995

申请日：2021-12-17

Applicant: KINIKSA PHARMACEUTICALS, LTD. ,  KINIKSA PHARMACEUTICALS CORP.

Inventor： JANG, Mei ,  NICHOLS, Dave ,  HUANG, Baochuan ,  GRIER, Shaun

IPC: C07K16/06 ,  C07K16/28 ,  C07K16/065 ,  C07K16/2866 ,  C07K2317/21

Abstract: The instant invention relates to compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, e.g., an anti-GM-CSFRα antibody or antigen binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such compositions. Methods for using such compositions to treat a disorder, e.g., a GM-CSFRα-associated disorder, are also provided.

公开(公告)号：WO2022098638A2

公开(公告)日：2022-05-12

申请号：PCT/US2021/057694

申请日：2021-11-02

Applicant: GENENTECH, INC.

Inventor： LI, Chi-Chung ,  O'HEAR, Carol, Elaine ,  BENDER, Brendan, Christian

IPC: A61P35/02 ,  C07K16/28 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K31/573 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2866 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/565

Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).

公开(公告)号：WO2021262561A1

公开(公告)日：2021-12-30

申请号：PCT/US2021/038170

申请日：2021-06-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： SCHIEVEN, Gary L. ,  DUDHGAONKAR, Shailesh ,  DOYLE, Michael Louis

IPC: A61K45/06 ,  A61K38/17 ,  A61P19/02 ,  C07K16/28 ,  A61K31/4545 ,  A61K38/1793 ,  C07K16/00 ,  C07K16/18 ,  C07K16/2866 ,  C07K2319/30 ,  C07K2319/32

Abstract: Disclosed is a method of treating rheumatoid arthritis, comprising administering to a patient a therapeutically effective dose of a TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a TNFα inhibitor.

公开(公告)号：WO2021239928A2

公开(公告)日：2021-12-02

申请号：PCT/EP2021/064312

申请日：2021-05-28

Applicant: ASTRAZENECA AB

Inventor： SINIBALDI, Dominic ,  WHITE, Wendy ,  SMITH, Michael ,  CASEY, Kerry ,  ILLEI, Gabor

IPC: C07K16/28 ,  A61P9/10 ,  C07K16/2866 ,  C07K2317/76

Abstract: The disclosure relates to methods for the treatment of, or for reducing the risk for development of, a cardiometabolic in a patient using an inhibitor of type I IFN signalling.

公开(公告)号：WO2021202731A1

公开(公告)日：2021-10-07

申请号：PCT/US2021/025171

申请日：2021-03-31

Applicant: CHEMOCENTRYX, INC.

Inventor： CAMPBELL, James ,  CHARO, Israel ,  SCHALL, Thomas ,  SINGH, Rajinder ,  ZENG, Yibin ,  ZHANG, Penglie

IPC: A61K31/18 ,  A61K31/4155 ,  A61K31/498 ,  A61P1/04 ,  C07D231/14 ,  C07D237/00 ,  A61K31/4402 ,  A61K31/4709 ,  A61P1/00 ,  C07K16/244 ,  C07K16/2866

Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.